Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has announced that the FDA has approved the Promus everolimus-eluting coronary stent system for the treatment of coronary artery disease.
Subscribe to our email newsletter
Boston Scientific’s Promus stent is a private-labeled Xience V everolimus-eluting coronary stent system manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant by Boston Scientific.
The Promus stent is said to expand Boston Scientific’s drug-eluting stent (DES) portfolio, which includes the Taxus Express2 paclitaxel-eluting coronary stent system (in the US and international markets) and the Taxus Liberte paclitaxel-eluting coronary stent system (in international markets), making Boston Scientific the only company to offer physicians the choice of two distinct drugs (paclitaxel and everolimus) on separate DES platforms.
Boston Scientific’s Promus stent and Abbott’s Xience V Stent are identical products sold by the respective companies under different brand names. FDA approval clears the way for Boston Scientific to launch the Promus stent immediately in the US.
Jim Tobin, president and CEO of Boston Scientific, said: “Promus stent complements our broad DES portfolio and further reinforces Boston Scientific’s leadership in the DES market, as well as our commitment to continued innovation and improved patient outcomes.”